Business
Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022
Biomea to present preclinical data from multiple in vivo studiesBiomea plans to initiate a Phase I/II clinical trial of BMF-219 in diabetes in the second half
About this update from Biomea Fusion, Inc.
[{"type":"text","content":"Biomea to present preclinical data from multiple in vivo studiesBiomea plans to initiate a Phase I/II clinical trial of BMF-219 in diabetes in the second half of 2022, subject to submission and clearance of an investigational new drug (IND) application REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that an abstract has been accepted at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions. The ADA 82nd Scientific Sessions will be held from June 3-7, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA. “We are very excited that our abstract highlighting preclinical in vivo data has been accepted for presentation at this year’s American Diabetes Association Scientific Sessions. This is a significant milestone for our company as we work to advance BMF-219 toward the clinic later this year as a treatment for type 2 diabetes, marking the second therapeutic area we will evaluate with this product candidate in addition to multiple cancer types. Based on its unique profile, we believe BMF-219 has the potential to deliver a truly novel, orally administered treatment with a durable effect for type 2 diabetes,” said Thomas Butler, Biomea’s CEO and Chairman of the Board. Biomea will disclose additional information about the presentation in alignment with the American Diabetes Association’s abstract embargo policies. About Menin in Diabetes Loss of functional beta-cell mass is a core component of the natural history in both types of diabetes — type 1 diabetes (mediated by autoimmune dysfunction) and type 2 diabetes (mediated by metabolic dysfunction). Beta-cells are found in the pancreas and are responsible for the synthesis and secretion of insulin. Insulin is a hormone that helps the body use glucose for energy and helps control blood glucose levels. In patients with diabetes, beta-cell mass and function are diminished, leading to insufficient insulin secretion and hyperglycemia. Menin is thought to act as a brake on beta-cell turnover / beta-cell growth, supporting the notion that inhibition of menin could lead to ...